NCT00121303View on ClinicalTrials.gov

Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

PHASE3CompletedINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

June 30, 2016

Conditions

LeukemiaMyelodysplastic Syndromes

Interventions

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

gemtuzumab ozogamicin

Trial Locations (6)

RG24 9NA

North Hampshire Hospital, Basingstoke

CT2 7NR

Kent and Canterbury Hospital, Canterbury

ME7 5NY

Medway Maritime Hospital, Gillingham Kent

ME16 9QQ

Maidstone Hospital, Maidstone

TR1 3LJ

Royal Cornwall Hospital, Truro, Cornwall

CF14 4XW

University Hospital of Wales, Cardiff

All Listed Sponsors

lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER

NCT00121303 - Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter